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Two Proposals to Lower Prescription Drug Prices: Generic Name
Prescribing & Repeal of the Antisubstitution Laws
The new public awareness toward prescription drug prices can be
attributed in large part to Wisconsin Senator Gaylord Nelson, and his
efforts as Chairman of the Monopoly Subcommittee of the Senate Select
Small Business Committee.' As an investigatory body, the Monopoly
Subcommittee has held hearings since May, 1967, dealing with the costs
of prescription drugs, the profits of drug manufacturers, and other aspects
of the prescription drug industry. 2 The findings of the Subcommittee have
been made available to the public, largely through coverage by the news
media. Public attention has also been drawn by the positive action taken by
Senator Nelson in the form of bills he has introduced into the United
States Senate to curb what he believes to be exorbitantly high prices in
a noncompetitive industry. He advocates the use of generic name prescribing to help reduce the price of prescription drugs.
Generic name prescribing is often thought of in conjunction with
antisubstitution laws, although antisubstitution is actually a much broader
concept. The meaning of these terms will become clear as the topics are
developed herein. Prescription by "generic name only" will be dealt 4th as a
proposal on the federal level to reduce drug prices; whereas antisubstitution
for the purpose of this paper will be limited to state proposals that have
the same goal.
A drug is alternately referred to by its chemical name, its brand name,
or its generic name. The chemical name refers to the chemical or molecular structure; the brand name is the name by which a drug is referred
to by its manufacturer; and the generic name refers to its established or
nonproprietary name. 3 In other words, brand names distinguish the product
of one company from another, while generic names never mention the
manufacturer's name. A drug usually has only one generic name, but it
can have as many brand names as it has manufacturers. Physicians can
usually tell the chemical make up of a drug by looking at its generic name,
because it is often an abbreviation of the chemical name. Brand names,
I James L. Goddard, former commissioner of the FDA, believes that the public is not
aware of prescription drug prices. His impression is that the increased consciousness of
drug prices may be on the part of law makers rather than on the part of the public. But see
Goddard, The Drug Establishment, ESQUIRE, March, 1969, at 116.
2

STAFF OF SUBCOMMITTEE ON MONOPOLY, SENATE SELECT COMMITTEE ON SMALL

BUSINESS, 92N CONG., 2D SESS., COMPETITIVE PROBLEMS IN THE DRUG INDUSTRYSUMMARY AND ANALYSIS v (Comm. Print 1972).
3 Food Drug and Cosmetics Act, 21 U.S.C. § 352 (e)(2) (1967); PHARMACEUTICAL MANUFACTURERS ASSOCIATION, BRANDS, GENERICS, PRICES AND QUALITY-THE PRESCRIBING DEBATE AFTER A DECADE 2 (1971)
[hereinafter cited as BRANDS AND
GENERICS]; Deichmann, Proprietary Drugs v. Generic Drugs, 35 GENERAL PRACTICE 174

(1967).
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on the other hand, do not indicate the chemical make up of a drug. 4
Amendments to the Federal Food, Drug and Cosmetic Act, require
drug companies to write the generic name beside the brand name, in type
at least one-half as large as the brand name, to be repeated each time the
brand name is featured. 5 At the time this regulation was promulgated,
it was hoped by the Food and Drug Administration (FDA), that doctors
would prescribe generically once they were aware that a drug was required
6
to be made available by its generic name.
Senator Nelson, displeased with the lack of voluntary generic prescribing by physicians, has advocated a change in the present law because
he feels a savings would result to the customer if doctors were required
to prescribe by "generic name only," rather than by brand name. He introduced a proposed amendment to the Federal Food, Drug and Cosmetic
Act on October 30, 1973, which would, ". . . prohibit the use of any name in
connection with any prescription drug other than the official name desig7
nated for such drug by The Secretary of Health, Education, and Welfare.'
The official name referred to would probably be an abbreviation of the
chemical name, or, the generic name, and would be the only one that can
appear on any label or advertisement. Consequently, the drug manufacturer
could not include the name of the company producing the drug or the brand
name. In effect, the same drug manufactured by every company would be
called by the same name. The pharmacist, in turn, would fill a doctor's
prescription with the brand he had in stock, which he purchased in the
competitive market. The majority of drugs have only one manufacturer,
so the pharmacist would have no choice in filling most orders, but in the
remaining cases, he would have a choice.
An antisubstitution law is one that requires a pharmacist to dispense
the exact drug the physician has prescribed. Every state, with the exception
of Kentucky, Maryland and the District of Columbia, has such a law.8 The
North Carolina antisubstitution statute, typical of most, reads in part:
Any person or corporation engaged in the business of selling drugs,
medicines, chemicals, or preparations for medical use or of compounding or dispensing physicians' prescriptions, who shall
...knowingly sell or deliver to any person a drug other or different from the drug.., ordered or called for by such person,
or called for in a physician's prescription, shall be guilty of a misdemeanor. ....
9

The antisubstitution laws were initially passed so that the unethical
Ruge, PrescriptionDrug Advertising, 32 LAW & CONTEMP. PIROB. 654 (1967).
' Food Drug and Cosmetic Act, 21 U.S.C. § 352 (e)(1)(B) (1967).
6 Ruge, supra note 4, at 656.
S. 2633, 93rd Cong., IstSess. (1973).
s Health Research Group, An Outline for Consumer Action On Prescription Drug Prices,
No. 56, Jan. 22, 1973, at 5.
9 N.C. GEN. STAT. § 90-76 (1937).
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pharmacist could not substitute one chemical drug for another without
breaking the law.' 0 As in many such laws," no mention of the word
"generic" or "brand" is made in the North Carolina antisubstitution
statute.'2 In the 1950's, the National Pharmaceutical Council interpreted
such legislation to mean a pharmacist could not substitute a generic name
for a brand name drug.' 3 This interpretation still holds true today, and
restricts the pharmacist to the brand name specified. On the other hand,
if the physician wrote the prescription order using the generic name of the
drug, then the pharmacist could choose which brand name drug he would
use in filling the order.
While on the federal level Nelson has strived to achieve generic name
prescription, on the state level, parallel forces are striving to achieve
a repeal of the state antisubstitution laws to allow pharmacists to substitute a cheaper generic name drug for the predictably more expensive brand name drug. The antisubstitution issue is not limited to generic name prescribing, even though it is often so construed. It also
means that one brand name drug cannot be substituted for another brand
name though they are the same chemical drug.
If a state does repeal its antisubstitution law, then the pharmacist would
be allowed to fill an order for a prescription with any brand or generic
name drug that is chemically the same as the drug prescribed. If Nelson's
amendment to the Federal Food, Drug and Cosmetic Act is passed,
any state without an antisubstitution law would have one official name
for each chemical compound, thus obviating the brand name/generic name
issue. The passage of the amendment, without a state's repeal of the
antisubstitution law would point the impact of "substitution" back to
its initial meaning, which was to stop pharmacists from dispensing
one chemical drug in place of another, omitting any reference to brand
names.
The essential point is that there are individuals and organizations
working at the federal and state levels to reduce the price of prescription
drugs. The repeal of the state antisubstitution laws and the federal bill to
require "generic name only" prescribing are two tools with which this goal
is being sought. There are many more. For example, an administrative
agency may simply make a ruling, thus obviating the necessity of a bill
passage through Congress. To illustrate, HEW Secretary, Caspar W.
Weinberger, ". . . plans to limit drug reimbursements under Medicare
and Medicaid to the lowest cost at which the drug is generally available
unless there is a demonstrated difference in therapeutic effect."'14 This
10Health Research Group, supra note 8, at 5; Editorial, The Plea of a Jacksonville Druggist, 220 J.A.M.A. 853 (1972).
" Health Research Group, supra note 8, at 5.
12 N.C. GEN. STAT. 90-76 (1937).
'3 Health Research Group, supra note 8, at 5.
'4 The News and Observer (Raleigh, N.C.), Dec. 20, 1973, at 3, col. 1.
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means that the government will shop for the best price. A doctor who
prescribes an expensive brand name drug rather than a cheaper generic
equivalent for his patients under these two programs, will have to justify
his reason for doing so before the government will reimburse him.
While brand name prescription and antisubstitution laws have their
enemies, they also have staunch advocates, who argue that prescription
drug prices are not high compared to costs in other major industries. This
comment will look at both sides of the antisubstitution controversy and
the pros and cons of "generic name only" prescriptions. Often the same
arguments used in support of the repeal of the antisubstitution laws will
be used for favoring generic name prescribing, but in other contexts, the
arguments for each will differ. Two important questions to keep in mind
while studying each side are, 1) whether prescription drug prices are too
high, and 2) if so, would the proposed remedies be effective in lowering the
prices.
There is a great deal of confusion today over the terms "generic" and
"brand." Often, "generic" is used to connote an inferior drug, this inference being due largely to the efforts made by the drug companies to
convince doctors to prescribe by brand names only. Often a generic product
is as effective as a brand name product. In fact, in many cases, the company
that produces a brand name will also produce generic drugs. For example,
Eli Lilly, one of the largest brand name drug manufacturers, also makes
generic drugs that can compete with any brand name of the same drug
on the market. There are good and bad brand name producers and good
and bad generic name producers.' 5
Nelson believes that doctors have been "sold" by the major drug companies to prescribe their brand name products, which are generally more
expensive. 16 The result is that doctors prescribe the more expensive medicine, even in cases where the same company makes the identical drug
and sells it by both its generic name and its brand name. Another situation
is where one drug company charges much more for its brand name than
its competitor charges for the same drug manufactured under its generic
name. A look at the drug, Reserpine, for example, illustrates the great
differences in cost between the generic and brand names. The five major
drug companies that manufactured Reserpine by a brand name sold it
from a high of $46.00 to a low of $9.12. The eighteen generic manufacturers
wholesaled the same quantity of Reserpine from a high of $2.80 to a low
of $.58.17 Nelson's point is that the company that sells the drug for $.58
is making a profit, so there is no reason the same company or another
company should sell the same drug for $46.00, simply to reap an unconscionable profit.
15 Boston Herald Traveler, Aug. 11, 1969, at 10, col. 1.
16 119 CONG. REC. 10820 (daily ed. June 11, 1973).
17 R. BURACK, THE NEW HANDBOOK OF PRESCRIPTION DRUGs 314 (1970).
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There are also companies that sell their brand name Olrugs to pharmacists at very high prices and turn around and sell the very same drug by
its generic name to the United States government or other governments
for very little. For example, CIBA Company sold its brand name drug,
Serpasil, to druggists for $39.50, but charged the United States Department
of Defense only $.60 for the same quantity of the drug sold by its generic
name. 18
When questioned about the fact that Schering Corporation charges a
druggist $170.00 for the same amount of Metricorten for which it charges the
government only $8.20, Mr. Conzen, the president of the company, replied that sales are made on the basis of a two price system. In the price
established for the government, only incremental costs are included, consisting of the price of raw materials and the cost of labor. None of the manufacturing costs or business operation costs, such as research, administration and taxes, are considered. This is done so that the company may receive a government contract by submitting the lowest bid. This has significance to the company, because to win a government bid means that its
brand name product will be used in government hospitals, institutions
and military camps. Such use has promotional value, because physicians
prescribing the product in that context will continue to do so when they
leave government service. So while a company could not stay in business if
it charged druggists the same low price, it will go to great lengths to have its
product used by governmental institutions. 19
Accordingly, since it would seem that generic name drugs are generally
cheaper than brand name drugs, (at least on the wholesale level-from
the manufacturer to the druggist), Nelson argues that a law that would
require generic name prescribing would result in a savings to the customer.
There are at least two fallacies in that argument. The first is the presumption that generic name drugs are always cheaper than brand name drugs.
There are top quality generic manufacturers that spend a great deal of
money on research, testing and quality control devices, just like the brand
name producers. To cover these costs, and the cost of advertising to promote their generic drugs, these producers sell their drugs at a high price.
Since they spend the money to reach the doctor, who prescribes the drug,
their high priced drugs sell. Generic drugs of this top quality would not save
the public much money,
because they will often be in the same price range
20
as brand name drugs.
However, if it is assumed that most generic name drugs cost less than
brand name drugs on the wholesale level, as Nelson has pointed out in numerous examples, the second fallacy in his argument is that the pharmacist is
18

119 CONG. REC.

10821 (daily ed. June 11, 1973);

SUBCOMMITTEE ON MONOPOLY,

supra note 2, at 16.
"9
20

SUBCOMMITTEE ON MONOPOLY,

supra note 2, at 16.

Boston Herald Traveler, supra note 15, at 10, col. 1.
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going to pass the savings on to his customer. 21 With an "official name only"
prescribing rule, formerly brand name products would be forced to replace
their brand name labels with the official names and doctors would have to
write out prescription orders using the official names only. The higherpriced companies would be forced to reduce the price of their drugs to
compete on the open market for the pharmacists' business, and the pharmacist, who at one time had to buy the expensive brand name, could now
purchase the cheapest drug on the market to fill the doctor's prescription
order. It is still within the discretion of the individual pharmacist to decide
the price he will charge the customer. He can keep all the profit that he
has saved by buying the cheapest drug, or he can choose to pass some or
all of the savings on to the consumer. His decision would probably take
into consideration his overhead expenses and local competition.
Similar results could occur if the antisubstitution laws were repealed.
The only difference would be that a doctor could prescribe a brand name
drug that he favors, and the pharmacist could substitute a cheaper generic
drug that is chemically the same. Again, the choice belongs to the pharmacist, whether to pass along the savings to the customer, or pocket it himself.
There is very little evidence as to whether pharmacists pass on the
savings at the retail level, because most of the states have antisubstitution
laws and Nelson's amendment has not been passed to require generic
prescription. Nelson draws most of his conclusions about savings to
the customer by looking at the difference in wholesale price between generic
and brand name drugs, and from his extensive surveys in Washington, D.C.
area pharmacies. Thus, most of his evidence is speculation.
In a 1969 report, HEW's Task Force on Prescription Drugs listed
sixty-three drugs that were available generically at a lower price than the
brand name equivalents. There were 346 drugs that were not available
by a generic name, but had to be purchased from its one producer by its
brand name. The 409 drugs on the list represented 88 percent of all the
drugs prescribed for the over sixty-five population. Dealing with the sixtythree drugs that were available at a lower cost by their generic names, the
Task Force found that a 55.3 percent saving would result on the wholesale
level if these drugs were purchased generically. On the retail level, the
Task Force speculated that if the druggist charged $1.81 or $2.00 to dispense
the drugs in question, the savings to the customer would have been 6.1
percent or 5 percent respectively of what is presently being charged. The
indications are that pharmacists would pass on some of the savings to
their customers, the figure varying from store to store and taking many cost
figures into account. The Task Force implied that a similar savings would
22
occur if the antisubstitution laws were repealed.
The Price of a Generic Rx Drug, 35 CONSUMER REPORT 398 (1970).
HEW, TASK FORCE ON PRESCRIPTION DRUGS-FINAL REPORT, at 36 (1969)
[hereinafter cited as TASK FORCE FINAL REPORT]; BRANDS AND GENERICS, supra
note 3, at 21-23; Willig, The Prosubstitution Trend in Modern
Pharmacy Law,
21
22

6 U. MICH. J. LAW REFORM 17 (1972).
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The Pharmaceutical Manufacturers Association (PMA) points out
from using Task Force figures that it is doubtful that a five percent savings
would have occurred, especially if pharmacists did not fill the prescription
with the cheapest product on the market. Another factor to consider is that
the Task Force did not include administration costs when figuring the
five percent savings. HEW estimated that a program which emphasized
generic name prescribing would cost $11,600,000 the first year and then
figures would reduce the five
less each successive year. To include these
23
percent to a virtual absence of savings.
Proponents of the antisubstitution laws point out examples of cases
where pharmacists have broken the law and were tried and convicted
for illegally substituting one drug for another. In these reported cases,
pharmacists did not pass the savings on to their customers. Instead, each
had filled a prescription with a cheaper drug and had charged the price
24
of the drug the physician had prescribed.
However, there are other reports that refute the Task Force claim
that a large savings would result if generic name prescribing were mandatory. One such report compared ten thousand prescriptions of welfare
patients in Rhode Island in 1960.25 The state concluded that a two percent
savings would have resulted if the drug had been prescribed and filled
generically where possible. In May and June of 1967 the American Medical
Association released news of a survey it conducted in which 185 Chicago
pharmacies filled 686 prescriptions of seven disputed products.2 6 Its conclusion was that filling prescriptions generically would not mean an automatic savings to patients. In fact, the survey showed that the patient sometimes paid more for generic prescriptions.
The province of Alberta, Canada has permitted pharmacists to substitute generic name drugs for brand name drugs since 1962, that is, unless
the doctor specifically prohibits it. A 1972 report showed that the average
cost of prescriptions in Alberta had not reduced in the ten years. In fact,
Alberta led all provinces in 1970 with an average prescription price of
$4.46. Canada's national average was only $3.89.27

In considering the extent to which generic name prescribing may reduce
drug prices, another fact to keep in mind is that generic name prescriptions
themselves are rapidly increasing in price. For example, their average
23 BRANDS AND GENERICS, supra note 3, at 22-23.
24 Address entitled Some Perspectives on the Proposed Repeal of Pharmacy's Antisubstitution Laws, by Robert W. Hammel, Professor of Pharmacy Administration at Univ.
of Wisconsin, to the Rock County Pharmaceutical Association and to the Pierce-St. Croix
Pharmaceutical Society, in reprint by the Pharmaceutical Manufacturers Association, at 1.
25 BRANDS AND GENERICS, supra note 3, at 15-16.

21 Id. at 19.
27 Address entitled A Background Study of the Antisubstitution Laws and the Brand

Interchange Concept, by the National Association of Retail Druggists, to the membership
at the 74th Annual Convention, Oct. 1-5, 1972, in reprint by N.A.R.D., at 7.
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price increased 63.2 percent between 1959 and 1969. Retail prescription
charges did not increase nearly as much. Between 1964 and 1969, the
difference in cost between generic prescriptions and prescriptions in general narrowed by one-third. The Pharmaceutical Manufacturers Association
28
suggests that there may be no difference within five years.
In an attempt to convince Congress to adopt his bill requiring generic
name prescriptions, Senator Nelson has pointed out how much more
Americans pay than foreigners for the same brand name drug. For example, Valium costs the druggist in England $2.88 for one hundred 5 mg.
tablets, and the druggist in America $8.10 for the same amount. One hundred 10 mg. capsules of Librium cost $2.40 in England and $6.82 in the
United States. While this seems like quite a difference, Nelson' finds it
even more astonishing that the British Ministry For Trade and Consumer
Affairs was able to order Hoffman-LaRoche, a Swiss firm, to reduce the
price of Valium and Librium, by 75 percent and 60 percent respectively,
because the Monopoly's Commission found that the firm controlled 68
percent of the tranquilizer market in the United Kingdom. The Commission
29
found that Roche was enjoying a 70 percent return on the capital.
The United States druggist pays almost three times as much for Valium
and Librium than the British druggist, yet Roche does not have to reduce
its price in the United States. The United States government, unlike the
British government, does not have the authority to require a company to
sell a drug at a lower price, even when Valium and Librium, number one
and three in sales in the United States, will total more than one quarter of
a billion dollars in 1973. Drug companies, such as Roche, that try to
justify receiving a seventy percent profit, argue that competitive market
conditions determine drug prices and keep them within reasonable
bounds. Roche cites 600 other products with which it competes. The British
government disagreed with this contention by putting Roche's products in
a class by themselves, since the total sales of the competitors only amounted
to one percent of the market. Drug companies argue trust in a brand name
as the reason doctors prescribe a certain drug, but opponents believe
the reason to be the seventeen year statutory patent, and prescription of
the same drug thereafter due to force of habit. 30
The American patent system allows a brand name product to dominate
the market for seventeen years without competition. The patent holder
does not even have to be the company that spent the time and money researching, testing and developing the drug. The originator can sell the
patent rights to another company, thus giving it the exclusive right to
sell the drug in the United States. Senator Nelson sees the monopolistic
2s BRANDS AND GENERICS, supra note 3, at 25.
29 119 CONG. REC. 19636 (daily ed. Oct. 30, 1973).
30 Id.
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patenting and licensing policies in the United States as another reason
drugs are higher priced here than abroad. By the time generics can enter
the field with lower prices seventeen years later, brand name prescribing
habits keep the original manufacturer on top, and reduced prices are not
31
necessary to retain customers.
Prescription drug manufacturers also contend that drug prices are not
high compared to prices in other industries and in comparison to other
health related fields. Figures show that of all the areas of expenditures
in the medical field, that of drugs requires the least amount of outlay,
32
and its price growth rate has increased less than the other areas.
When drug prices are compared to prices outside the drug industry,
the Wholesale Price Index, put out by the Department of Labor's
Bureau of Labor Statistics, shows that the level of all commodities has
33
risen since 1965, while the price level of prescription drugs has declined.
Another observation shows that between 1957 and 1971, the average prescription cost rose only two percent, and when an increase in the package
3 4
size was taken into account, the price actually declined by three percent.
Other government reports show a rise in the price of consumer goods
in 1972 by 3.3 percent, and in medical care by 8.4 percent. In contrast,
the increase of prescription drug prices in the same year was only 0.4 percent,
which was only the fourth increase in over fourteen years. In fact, since
1962, there has actually been a nine percent decrease in retail prescription
drug prices.35

Senator Kefauver, ideological predecessor of Senator Nelson, argued
that doctors prescribed by brand name even after the seventeen year patent
period ended because of the promotion campaign run by major drug companies, and because of force of habit. He would have had the people believe that the most expensive brand name of each generic drug had a monopoly in its field. As proof, he quoted the prices of two drugs, Reserpine
and Prednisone, which were manufacatured by their originators and sold
for exorbitant prices, and sold subsequently by other companies under their
generic names at greatly reduced prices. However, Kefauver quoted
only the great differences in prices between the brand and generic name
drugs. He never told the public that the original manufacturers lost the
market to the companies that sold the drugs generically. This would at least
in part refute Kefauver's, and later Nelson's claim, that doctors continue
31 119 CONG. REC. !2782 (daily ed. July 9, 1973); SUBCOMMITTEE ON MONOPOLY,
supra note 2, at 25.
32 HEW, NAT'L CENTER FOR SOCIAL STATISTICS REP. (chart prepared and released by
Nat'l Pharmaceutical Council, Washington, D.C.) nos. B-2 (FY-70), B-5 (FY-70), F-I
(FY-70), F-3 (FY-70), (Mar. 1973).
33 PHARMACEUTICAL MANUFACTURERS ASS'N, PRESCRIPTION DRUG INDUSTRY FACT

BOOK 22 (1972) [hereinafter cited as PMA FACT BOOK].
34 Id. at 25-26.
35 Id. at 28.
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original brand name when cheaper brand or generic names
to prescribe the
36
are available.
The point is that the doctor will often be controlled by the market when
there is more than one drug available of the same quality. Thus, the market
place has a reductive effect on drug prices to this extent in instances where
a competitive market exists. Promotion and habit may play a role in the
decision of a doctor when he fills a prescription, but today many doctors
are becoming increasingly aware of price differences and will prescribe
with this in mind if they trust the product. In cases where doctors are
reluctant to change, it may be because they have either developed a trust in
the brand they already know, or they are not familiar with the other drugs
that may be available at a cheaper price.
The responsibility for prescribing a drug to a patient is presently on
the doctor. The American Pharmaceutical Association, made up of one
of every three pharmacists, is supporting measures that would repeal the
state antisubstitution laws. 37 In effect, this would take the control over
the prescription of drugs out of the hands of the doctors, the only persons
who have knowledge of the patient's medical history, and leave it to the discretion of the pharmacist. The danger of this practice becomes paramount
when illustrated by the argument of therapeutic equivalency as distinguished from chemical equivalency.
Rather than repeal sorely needed antisubstitution laws, the American
Medical Association (AMA) recommends retention of them, and interprofessional communications between physicians and pharmacists. Consultation on generic substitution and drug prices can make doctors aware
of the great differences in prices between drugs, and of the high quality
of drugs they never before bothered to prescribe. Doctors should be encouraged to write prescriptions using the generic name when they feel all
companies' drugs are the same. This allows the doctor to control the
situation, as it should be, and to shift the burden of choice to the pharmacist only on proper occasions. However, the doctor should retain the power
brand is of better
to prescribe by brand name when he feels that a particular
38
quality than brands put out by other companies.
The AMA has refuted the American Pharmaceutical Association's
argument that a pharmacist is best qualified to prescribe drugs because of
his knowledge of drugs. The AMA contends that the pharmacist generally
has no more information on the drug than the doctors, and that the doctor,
unlike the pharmacist, has no economic impetus to stock the cheapest
drug in order to realize a larger profit on its sale. Additionally, a pharmacist,
regardless of the extent of his technical knowledge of medicines, has not
36 BRANDS AND GENERICS, supra note 3, at 14-15.
3, Editorial, Substitution of Drugs, 212 J.A.M.A. 1369 (1970).
38 Id.
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examined the patient. These three factors point to the doctor as being
39
best qualified to prescribe drugs.
Nelson believes that the promotion of prescription drugs by major
companies has been a vital factor in keeping brand name drugs more costly
than generic name products. In 1971, the sale of drugs amounted to four
billion dollars, 25 percent of which was spent for advertising and promotion.
On the average, drug companies spend about $5,000 a year for each of the
200,000 doctors in the United States, in order to convince them to prescribe certain drugs. 40 He states that high powered advertising has not
only increased the price of drugs but has also convinced doctors that expensive drugs are more reliable than generic drugs. 4 1 Nelson believes
that this promotion encourages doctors to prescribe drugs even when they
are unnecessary. Madison Avenue advertising firms design ads so that a
drug can be prescribed to cover a wide range of symptoms, many being
just the ordinary frustrations of daily living. A considerable number of
claims made by drug advertisements are false, but by the time the FDA
requires the company to run a corrective ad saying the drug does not do
everything it was promoted to do, it is too late-the initial promotional
drive was
so great that the drug continues to benefit from the false cam42
paign.
Studies reveal that doctors receive most of their information on drugs
from detail men who sell them the drugs, journal advertisements, direct
43
mail advertisements, and samples, all of which Nelson labels as biased.
The Journal of the American Medical.Association, one of three hundred

regularly published United States medical journals, receives one half
of its twenty million dollar annual budget from advertising. 44 Approximately $700 million of the manufacturers' advertising budget is spent
with detail men who are drug company salesmen. 45 Results of such expenditures are shown in one study which revealed that 46 percent of the
doctors in general practice base their decisions on whether or not to pre46
scribe a drug solely upon the word of detail men.
The PMA represents 135 major drug companies. Although eighty are
major operations, thirty-five of them actually control the drug industry.
Because these thirty-five are able to afford the best advertising, both in
quantity and quality, doctors may be brain-washed into believing the drugs
presented favorably in these ads are the best. Since doctors prescribe
Editorial, Drug Substitution-How to Turn Order Into Chaos, 217 J.A.M.A. 818 (1971).
Other sources quote figures to be as low as $3,000 and $3,750 per doctor. Goddard,
supra note 1, at 152; Ashe, Detail Men and Doctors, 4 BEVERLY HILLS B.J. 15 (1970).
41 119 CONG. REC. 10821 (daily ed. June 11, 1973).
42 119 CONG. REC. 2059 (daily ed. Feb. 5, 1973).
43 119 CONG. REC. 2961 (daily ed. Feb. 21, 1973).
44 Ashe, supra note 40, at 15.
45 119 CONG. REC. 2059 (daily ed. Feb. 5, 1973).
39

40

46 H. DOWLING, MEDICINES FOR MAN-THE DEVELOPMENT, REGULATION, AND USE
OF PRESCRIPTION DRUGS 274 (1970).
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these expensive brand name drugs with which they are most familiar,
competition may be effectively eliminated, thus allowing a few dominating
47
companies to charge exorbitant prices.
However, the PMA holds that the drug market is highly competitive,
and that the degree of concentration of influence within the hands of a few
is markedly below that found in a majority of the other industries. To
illustrate how competitive the industry is, the PMA points out the number
of new products on the market, and the number of companies that either
rose to or fell from the rankings on the list of the top one hundred companies
48
in the new prescription market, according to net sales.
In order to justify high drug prices, manufacturers contend that investment in drug research involves a substantial element of risk, and that therefore it is necessary to have high profit margins to attract research investors.
For example, of every six thousand compounds tested by manufacturers,
only one becomes marketable. The drug industry spends more for research
and clinical testing than any other industry; and even when a new drug
reaches the market, another new drug could come along and replace it
49
before any profit is realized.
To refute the claim of the drug industry about the burden of research
expenditures, Nelson states that the 6.2 percent of their annual sales that
they do so spend, is not very large compared to the 25 percent they
spend on advertisements and _promotion. 5 0 In addition, much of the
research by the various companies is duplicative and is not primarily intended to advance medical progress, as drug companies tend to imitate
drugs that have proven successful on the market. 5 1 Nelson believes that the
risk factor is induced by the industry itself, because of "copying" companies continually coming up with similar rather than new drugs. 52 Evidence shows no companies going out of business because of the risks
involved or the losses suffered. 53 According to Nelson's findings, private
American drug companies have over-distorted facts, in order to take credit
for much of the research performed by the United States and foreign gov54
ernments.
Drug companies argue that it is this continual research which produces
new and better drugs. By giving the power of selection to the pharmacist
through repeal of the antisubstitution laws, drug research would be stifled
47 Goddard, supra note i, at i16. The PMA recognizes its active membership to be
115 firms rather than 135. PMA FACT BOOK, supra note 33, introduction.
41 PMA FACT BOOK, supra note 33, at 12-13.
49 SUBCOMMITTEE ON MONOPOLY, supra note 2, at 31-32.
5o 119 CONG. REC. 2961 (daily ed. Feb. 21, 1973).
51 Id.; TASK FORCE FINAL REPORT, supra note 22, at 8; Goddard, supra note i, at 121.
52 SUBCOMMITTEE ON MONOPOLY, supra note 2, at 32-33. The similar drug is just

different enough not to infringe on the originator's seventeen year patent right. Goddard,
supra note 1,at 121.
13 SUBCOMMITTEE ON MONOPOLY, supra note
14 Sanford, In Brands We Trust, 158 THE NEW
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because the doctor prescription has always been the method by which new
drugs have been accepted and recognized. To do otherwise would impede
55
medical progress.
The drug industry often quotes the figure of eighteen dollars as the
amount an American spends on prescription drugs each year. This amount,
when compared with amounts spent on other products, is seen to be
reasonable. Critics reply that eighteen dollars is not indicative of where the
major burden of drug prices falls. For instance, those over sixty-five
years of age make up only 10 percent of the population, yet they buy over
25 percent of the prescription drugs, thus spending considerably more
than eighteen dollars a year. This group lives on a fixed income and is least
56
able to afford high drug prices.
Many of the poor in our society find themselves in the same situation
involving a fixed income, often because they receive some type of public
assistance. Due to their poor health surroundings, they incur heavier
expenditures than the eighteen dollars per year would indicate. Thus, the
poor, the elderly, and any other person who must take daily medication,
carries the brunt of the burden of high drug prices. Nelson sees "generic
name only" prescriptions as a way to help reduce the prices to these seg57
ments of our population.
Drug companies argue that to require generic prescription or repeal
the state antisubstitution laws would not necessarily effect prices charged,
because it is still up to the pharmacist to pass the savings on to the customer
when he fills a prescription generically. Some surveys have shown that
ghetto drug stores often charge high prices for prescription drugs for a number of reasons. Ghetto customers are often not aware of the large differences
in prices between stores; people often find it cumbersome to obtain transportation out of their local area to price shop; and they quite often do
not feel well enough to shop around for the best prices. Thus, their local
druggists often charge whatever price the market will bear.58
There are some who believe that a repeal of the antisubstitution laws
would lead to cut-rating techniques and customers would find it worthwhile to shop for the lowest price. This interaction, Nelson believes, would
stimulate competition and therefore lower prices. While theoretically the
idea is good, its practical application could lead to serious problems. Some
druggists would stock a drug while others would refuse to do so because
of its questionable quality. The danger exists that ethical pharmacists
may be pressured into ordering inferior goods in order to compete with
those who would order the cheapest drugs in an attempt to win the public's
55 Goddard, supra note I, at 121.
56 119 CONG. REC. 10820 (daily ed. June 11, 1973); Health Research Group, supra
note 8, at 2.
51 Health Research Group, supra note 8, at 2.
58Daylight on Prescription Drugs, MONEY, Oct., 1972, at 31-33.
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While Nelson's main reason for wanting to prohibit the use of any
brand name other than an official or generic one is to lower the price, he
also wants to clear up the confusion resulting from having more than one
name for the same drug. There are over 200,000 prescription drug products
on the market, but only seven hundred different drug compounds. The
different names,
antibiotic, tetracycline, for example, has over twenty-four
60
all of which have met the same government standards.
While some advocate elimination of brand name prescribing in order
to avoid mistakes and increase public safety, 6 1 others believe that the original manufacturer's name should appear on the label in order not to mislead
or confuse those buying drugs. Those who favor this view believe that
doctors should rely on reputable manufacturers because of the consistency
in quality of the drugs they produce. To prescribe by generic name only
would mean that a patient could be given a drug that is manufactured by
62
a marginal or disreputable company.
One of the most contested areas in the fight over substitution is the
"generic equivalency" controversy. HEW's Task Force stated in its
report that the real issue is whether two drugs that are chemically equivalent will provide the same clinical affect. 6 3 Those who favor the repeal of
antisubstitution laws and "generic name only" prescribing, take the stand
that drugs that are chemically the same are equivalent to each other. Thus,
a generic name or cheaper brand name drug that has the same amount
of the same active ingredient in each dosage is equivalent to the better
known brand name product. Pro-equivalency forces argue that all drugs
manufactured in the United States have met the same chemical equivalency
standards set down by the Federal Food, Drug and Cosmetic Act, and
that therapeutic equivalency follows chemical equivalency. They also
point to statistics that show that there have been few reports of significant
differences in cases where chemical equivalents have been used over
64
long periods of time.
Although manufacturers (who support brand name prescriptions) argue
that chemical equivalency does not mean therapeutic equivalency, the
Task Force concluded after a limited study that nonequivalency arguments
were exaggerated. 65 The results of one study on 20,000 antibiotics over
9 Address entitled The Generic Issue, by Vernon Trygstad, President, Nat'l Pharmaceutical Council, to Mid-year meeting of the Ind. State Pharmaceutical Ass'n, in Richmond,
Ind., Jan. 21, 1968, in reprint by the Nat'l Pharmaceutical Council, at 18-19.
60 119 CONG. REC. 19637 (daily ed. Oct. 30, 1973).
61 Id.

61 Note, Products Liability for Prescription Drugs-The Effects of Generic Substitution
on the Consumer and the Pharmacist,23 SYRACUSE L. REV. 894-95 (1972).
63 TASK FORCE FINAL REPORT, supra note 22, at 31.
64 Willig, supra note 22, at 11-12.
65 TASK FORCE FINAL REPORT, supra note 22, at 31.
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a five year period concluded that there was no significant difference between brand and generic name antibiotics. 66 Another study on nineteen
other classes of drugs reached the same conclusion in 1970.67 Some prosubstitution forces agree in part but contend that while meeting the federal
standards does not guarantee equivalency it does insure purity and po68
tency.
The United States Pharmacopeia (USP) and the National Formulary
(NF) set forth standards that drugs have to meet in order to be classified
as effective. Any drug that meets these standards is classified as having
met them, and bears the mark of NF or USP. Both these compendia are
administered to by non-governmental bodies but they are recognized by
federal law as the official standards. 69 While all drugs must meet the USP or
NF requirements, it is possible for a drug to be put on the market without
having complied. This occurs when drug companies give the FDA information and data required to evaluate drugs in light of the published
standards. Since the companies have a financial interest in getting their
drugs on the market, they may distort or withhold vital information. Before
the drugs can be recalled by the FDA, time may elapse and the public may
be endangered by use of inferior drugs. Nelson has proposed a bill that
would establish a National Drug Testing and Evaluation Center, which he
hopes will reduce cost, the time consumed in testing drugs, and bias through
70
non-partisan evaluation.
There is nothing to stop a manufacturer from putting on the market a
drug that has not met any compendial test. The government only checks
to see if companies have complied with the requirements when an enforcement proceeding is involved. So when a drug meets the official requirements, this merely suggests that if it is ever tested it will have met
71
the minimal requirements .
Another way a drug can reach the market without complying is by being
a copying drug, which enters the market to compete with the original
manufacturer's product. It does not have to meet the rigid requirements
that the original drug had to meet. Since it only has to prove chemical
equivalency, the copying company saves money on research and testing
that could demonstrate therapeutic equivalency . 7 2 The effects of the original
and copying drugs upon the user may be different. The copying company is
66

119 CONG. REC. 10820 (daily ed. June 11, 1973).

67

Id.

2, at 46-53.
and Cosmetic Act, 21 U.S.C. §§ 351, 352 (b) (1967).
REC. 2961 (daily ed. Feb. 21, 1973).
7 Francke, Bioavailability of Digoxin, 6 DRUG INTELLIGENCE & CLINICAL PHARMACY
5 (1972); Willig, supra note 22, at 12.
72 There are those who believe that the imitating companies making chemical equivalents
should be required to do the same clinical testing as the original manufacturers, in order to
do away with inconsistent substandard drugs.
68

SUBCOMMITTEE ON MONOPOLY, supra note

69 Food Drug
70 119 CONG.
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able to produce the drug at a lower cost than the original manufacturer,
because the standards he must meet are less demanding financially. 73 To
claim therapeutic equivalency, the company would be required to provide
74
the results of further research and testing.
Bio-pharmaceutics is a new field of pharmaceutical science that has been
growing in importance since 1960. It seeks to determine how much of the
drug reaches its intended destination. For example. a drug that is chemically equivalent to another drug may not be therapeutically equivalent
because only part of the drug may reach the cells that are hoped to be
affected. Bio-availability refers to the ability of a drug to reach those cells.
If a drug takes three times longer to reach the cell and only three-fourths of
its ingredients arrive there, it is not therapeutically equivalent. To determine
how much will reach the cells, the amount of the drug must be measured
in the blood stream at different intervals from the time it is taken. A difference in blood level readings establishes a difference in therapeutic
effect.7"
Bio-availability, or biologic availability may also be called biologic
equivalence. Since there are no standards to require biologic equivalency,
doctors usually rely on reputable established manufacturers whose controls over quality are sufficiently reliable that a person taking the same
drug will receive the same effect each time the drug is used. Reputable
manufacturers, who maintain quality control, may be producers of brand
or generic name drugs. The point is that a patient should be given the
same company's drug each time, because drugs chemically the same
but made by different companies are not necessarily biologic equivalents.
The repeal of the antisubstitution laws would allow a pharmacist to change
one company's drug for another. A "generic name only" law would also
permit a pharmacist to fill an order with any brand he has on stock. Consequently, a patient would not be assured of getting the same effect each
time he takes a drug that is a chemical but not a biologic equivalent. 76
Tetracycline, for example, is produced by many companies, and available by its generic and brand name at a wide range of prices. The original
and most expensive sells under the brand name, Achromycin. Dr. Modell,
a professor of Pharmacology, thinks that the absorbtion pattern of this
anticoagulant is a critical factor and there are many Tetracycline products
on the market that absorb faster or slower than Achromycin, and are therefore thought by him to be inferior. It would seem that an assurance of
73 To say a drug is therapeutically equivalent to another is representing that it will have the
same effect as the other drug, even though it may differ chemically. Therapeutic equivalency
thus refers to effectiveness.
71 Pharmaceutical Manufacturers Ass'n, PMA Newsletter Supplement vol. 9 no. 48,
Dec. 1, 1967.
15 Products Liability, supra note 62, at 891.
76 Modell, Drug Equivalence and Fixed Combinations, MODERN MEDICINE, Sept. 6,
1971, at 43.
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constant effect would
be more important to the user of this drug than the
77
cost of the drug.
Digoxin, a drug often prescribed to elderly patients to treat cardiac
conditions, was developed by Burroughs Wellcome Company and given
the brand name of Lanoxin. After patent rights ended, other companies
began producing the drug and selling it under the generic name, Digoxin.
Doctors, aware of the difference in price and hoping to save their patients
money, began writing prescriptions generically, which allowed pharmacists
to fill the order with any brand he had in stock. When reports were substantiated that some of the generics were not of good quality, an investigation followed, which led to the recalling of forty-seven million tablets
from the market between October, 1968, and June, 1971, for failure to
pass the USP test. Thirty-seven companies had their products recalled,
but the original
manufacturer, Burroughs Wellcome, was not one of that
78
number.
Lanoxin, Burroughs Wellcome's brand of Digoxin, is recognized,
even by the FDA, as being of such high quality and predictability that
it has always been used as the standard measure for the other thirty-odd
Digox n products on the market. Clealand F. Baker, an executive of Burroughs Wellcome, stated that Lanoxin supplies over eighty percent of
the Digoxin in the United States today. Due to an effective quality control
system and years spent in costly research, Lanoxin has never been recalled
from the market. Mr. Baker believes that a doctor should rely7 9on the established reputation of the manufacturer when choosing a drug.
The above example brings out two points. The first is that it illustrates
non-equivalence; the second is that the FDA did not detect the substandard
drugs until they were already on the market. The public was exposed to the
inferior drugs until the recall procedure responded to the situation. This
process took time. The obvious conclusion is that the FDA cannot assure
us that all manufacturers will comply with the federal standards, and even
if that were possible some revision of the standards is necessary.8 0
There are many drugs put on the market by competing companies whose
biologic availability is suspect. 8 1 The originator's quality control system
11 Id. at 43-44.
71 Products

Liability, supra note 62, at 894.

79 Letter from Clealand Baker to the editor, in NSI3 J. AM. PHARMACEUTICAL AWS'N

602 (1973).
80 Products Liability, supra note 62, at 894-95.
81 Address by Dr. M. Pernarowski to the annual meeting of the Can. Pharmaceutical
Ass'n. at Vancouver, Aug., 1970, in 104 CAN. PHARMACEUTICAL J. 6 (1971); Pharmaceutical Manufacturers Ass'n, supra note 74; Blair, Barnes, Wildner, Murray, Biological
Availability of Oxytetracycline HCL Capsules, 215 J.A.M.A. 251 (1971); Letter from Dr.
George Brice and Dr. Henry Hammer to the editor, in 208 J.A.M.A. 1189 (1969); Dep't of
Pharmaceutical Sciences, Biological Availability, 5 DRUG INTELLIGENCE & CLINICAL
PHARMACY 117 (1969); Francke, supra note 71, at 5; Scheller, Status Report on Drug BioAvailability, 27 AM. J. HosP. PHARMACY 486 (1970).
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usually surpasses the required testing of the FDA. Laboratory tests and
clinical studies enable them to produce consistency %%dhin each batch
of drugs manufactured. Competing companies that copy the originator's
drug often include only the essential ingredients in order to pass FDA
standards, and2 have omitted additional expenditures necessary to assure
consistency.
If all producers were required to perform clinical testing, the probabilities of therapeutic equivalency would improve. 83 However, it should be
noted that such a requirement would entail great expenditures and thus
add to the costs the imitating companies would have to pass on to the consumer in the form of higher prices.
As the drug industry spoke out against the dangers of biologic nonequivalence, HEW's Task Force on Prescription Drugs concluded in
its 1969 Final Report that exact clinical or bio-equivalency was not important in the twenty percent of the drugs that could be duplicated. It
also stated that the non-equivalency argument had been exaggerated,
because there may be therapeutic value in a chemically equivalent drug
even if exact therapeutic equivalence does not exist. The Task Force
did, however, recognize the importance84of further study in instances where
exact bio-equivalence could be crucial.
One way to determine whether a drug meets the minimum standards
set by the FDA is to look at the recall records. This is not always to be
relied upon, though, as the testing procedures of the FDA allow many
substandard drugs that are on the market to escape detection for long periods of time. A list of recalls by the FDA shows the number of recalls of
products of twenty-six brand name companies with the total number of
recalls for prescription and over-the-counter drugs on a weekly basis between January 7, 1971 and December 22, 1971. The result indicated that
the number of recalls per week of products of the brand name companies
was a very small fraction of the number of total recalls, thus indicating
the quality and consistency that is put into brand name drugs. 85
The violations, as evidenced by the weekly drug recall lists, could be
partially eliminated if producers abided by "Good Manufacturing Practices" (G.M.P.), established by the FDA. Non-compliance with these
86
guidelines often bears a direct relationship to the number of drug recalls.
Consequently, it is logical to assume a causal relationship between laxity
in manufacturing procedures and products of inferior quality. To determine
Pharmaceutical Manufacturers Ass'n, supra note 74.
3, at 46.
14 TASK FORCE FINAL REPORT, supra note 22, at 31-32. The remaining 80 percent could
not be duplicated because they either had a patent or were under license.
85 HEW/NCSS, supra note 32.
86 Feinberg, Criteriafor the Procurementof Drugs, 6 DRUG INTELLIGENCE & CLINICAL
PHARMACY 63-64 (1972).
82

13 BRANDS AND GENERICS, supra note
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compliance or noncompliance and to enforce "Good Manufacturing
Practices," comprehensive inspections are needed.
The Federal Food, Drug and Cosmetic Act specifically requires the
FDA to inspect drug producers at least once every two years to make
sure they conform to "Good Manufacturing Practices. ' 8 8 A Report to the
Congress by The Comptroller General of the United States revealed that
many drug companies did not comply with the G.M.P. Even so, in cases
where deviations were potentially critical, the FDA did not enforce compliance. Due to lack of manpower, government inspectors concentrated
on inspecting the prescription drugs, and neglected the less potentially
harmful non-prescription drugs. The general conclusion to be drawn is that
the FDA is under pressure to enforce standards selectively because of its
limited manpower. A change in the laws that would allow generic name
drugs on the market in more frequent abundance would mean more inspections by an already overburdened staff. The Comptroller General's
report concluded that the FDA had no means to insure that every drug
producer would be inspected every two years. Also, a better inspection
system was found to be needed in order that all producers are reached.
It was recommended that new guidelines be established to insure early
87
inspection of new drugs.
If substitution laws or a "generic name only" law was passed, a better
inspection system would have to be created to sufficiently regulate the
entry of generics on the market. 88 This would require more personnel
in the Department of HEW, the parent of the FDA. Enactment of such a
law would necessitate a stricter enforcement policy by the FDA at the
production stage. This would add to the work load and increase the operational costs of the FDA.
CONCLUSION

As the public becomes aware of the disparity in prescription drug prices,
pressure builds to reduce those prices seen as excessive. Many advocates
of lower drug prices recommend the passage of an amendment to the Fedderal Food, Drug and Cosmetic Act, to require labeling and advertising by a drug's official or generic name only. On the state level,
measures are supported which would repeal the antisubstitution laws,
thereby allowing a pharmacist to substitute an equivalent drug other than the
one prescribed by the doctor.
It cannot be concluded that either of the above proposals will result
in lower prescription drug prices if enacted. While it is true that there are
LEMS

COMPTROLLER GENERAL OF THE U.S., REPORT TO THE CONGRESS ON THE PROBIN OBTAINING AND ENFORCING COMPLIANCE WiTH GOOD MANUFACTURING

PRACTICES FOR DRUGS B-164031(2), at 1, 32-35 (March 29, 1973).
88 Prescription by Generic Name Should Not Be Required, 118 J. LA. STATE MED.
Soc. 520 (1966).
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great price differences among similar drugs, and that generic name drugs
generally wholesale for much less than brand name drugs, it does not
necessarily follow that filling of prescriptions with the lowest-priced wholesale drugs will bring automatic savings to the ultimate consumer. In some
cases, druggists have not passed the savings to the customer, while in
others, he has passed on a partial savings. Even if it were conceded that
a pharmacist would pass on a partial savings, critics say that this slight
savings would disappear when administrative costs are added. Also, a
program which requires generic name prescribing would require large
expenditures on controls, in order to protect the consumer from substandard
products.
While consumer advocates argue that the price of prescription drugs
are too high, the major drug manufacturers argue that prices are not excessive compared to those in other industries. They point out that quality controls, research, and clinical testing make their drugs cost more than
drugs of "copying" manufacturers. Major drug producers believe that
a repeal of the state antisubstitution laws or the passage of a federal "generic
name only" law would jeopardize the quality of drugs and adversely affect research and growth in the drug industry. While these arguments
merit consideration, it should also be pointed out that the companies' interest would be directly affected by the enactment of the federal law on
the one hand, or the repeal of the state law on the other. They would be
forced to lower their prices to compete with the lower-priced drugs, or to
risk losing their business by maintaining relatively high prices.
Brand name drugs, as a general rule, cost more than generic name
drugs. However, even companies that produce generic name drugs may
charge high prices. This usually occurs because they, like producers of
brand name drugs, have spent a great deal of time and money on research,
testing and other good manufacturing practices. Conversely, the
companies that produce generic name drugs at a low price are generally
those which have not had to spend money on research and testing. Therefore, the controversy is not necessarily between generic and brand name
producers, but between well-respected brand and generic name manufacturers on the one hand, and smaller, less-respected generic name
manufacturers on the other. By cutting corners and reducing testing procedures, these latter producers are able to market drugs at substantially
lower prices, but with greater risk of harm to the consumer.
A change in the present laws would increase this problem by reducing
the power of physicians to specify a brand name he believes to be respectable, and by allowing the pharmacist to circumvent the physician's choice,
or by requiring the physician to prescribe only generically. According to
the proposed amendment to the federal law, the drug company's name
would not even be mentioned.
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The main reason to keep "generic name only" prescribing from becoming a reality, and to keep the antisubstitution laws intact is that one
drug is not the therapeutic or biologic equivalent of another and therefore
a substituted drug could produce undesired effects. Many who agree with
this statement admit that in many cases there would be no harmful effects where the substituted drug is chemically equivalent to the one originally prescribed. However, the fact that there are a few reported cases
where substitution has been harmful, and an indication that more reports
will follow as substitution proliferates, is sufficient grounds for arguing to
keep the federal and state safeguards as they are. Until a therapeutic or
biologic equivalency test can be established, changes in the present laws
would be premature, If in the future a doctor could prescribe a generic drug
with confidence that it would be therapeutically equivalent to the brand
name drug, and that it has been through extensive clinical tests-at that
point a change in the laws should be considered.
If prescription drug prices are indeed too high, then other remedies besides allowing substitution or generic prescribing should be considered
to lower them. It has not been sufficiently proven that the proposed changes
would result in a savings to the consumer. However, even if there was a
savings, as long as there are even a few cases of therapeutic nonequivalency
and the subsequent danger of serious or fatal injury occurring from this
lack of equivalency, the present laws should remain intact.
MICHAEL DANA MASON

Equal Protection in Legislative Apportionment:
A New Double Standard
INTRODUCTION: MALAPPORTIONMENT: INEQUALITY AND
THE INDIVIDUAL'S VOTE
1

In Mahan v. Howell, the Supreme Court gave legal sanction to limited
malapportionment. In this apparent reversal of its prior stance, the Court
in Mahan held, inter alia, that a Virginia statute which apportioned the
House of Delegates by traditional county and city boundaries was valid
93 S. Ct. 979 (1973). The Virginia statute provided for a combination of 52 single-member
multi-member, and floater districts from which 100 delegates were to be elected. 93 S.Ct.
at 980. The term 'floterial district' is used to refer to a legislative district which includes within
its boundaries several separate districts or political subdivisions which independently would
not be entitled to additional representation but whose combined population entitled the entire
area to another seat in the particular legislative body being apportioned. Davis v. Mann,
377 U.S. 675, 686 (1964).
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